No Data
No Data
Investors Don't See Light At End Of Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Tunnel
Humanwell Healthcare Subsidiary Gets Clinical Trial Approval for Schizophrenia Medication
Humanwell Healthcare Registers Antidepression Drug
Sinolink: The rising enthusiasm for HEALTH CARE A applications is worth investing in; the traditional main line may welcome a reversal in the quarterly reports.
With the development and progress of AI technology, AI continuously makes new advancements in empowering medical and healthcare, promoting industry upgrades, and its application in the medical and health field is expected to enter an accelerated development stage.
Humanwell Healthcare (600079.SH): Dimethyl fumarate enteric-coated capsules have obtained a pharmaceutical registration certificate.
On February 10, Glonghui reported that Humanwell Healthcare (600079.SH) announced that its holding subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for Dimethyl Fumarate Enteric Capsules. Dimethyl Fumarate Enteric Capsules are used for the treatment of adult patients with relapsing forms of multiple sclerosis: including clinically isolated syndrome, relapsing-remitting, and active secondary progressive.
Humanwell Healthcare (600079.SH): Elected Director Zhou Hansheng as Chairman.
Humanwell Healthcare (600079.SH) announced that the Board of Directors received company information on January 23, 2025...